Metaphorics, Syrrx Ink Ligand-Docking Partnership | GenomeWeb

NEW YORK, March 1 - Bioinformatics company Metaphorics has struck a  research collaboration with drug-discovery firm Syrrx designed to improve computational tools for docking ligand molecule structures into protein binding sites.

The companies said on Thursday that the collaboration seeks to create new software that might help scientists better predict "the potential complementarity" between ligands and proteins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.